Apollomics, Inc. (APLM) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Foster City, CA, アメリカ. 現CEOは Hung-Wen Chen.
APLM を有する IPO日 2021-11-26, 13 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $15.75M.
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
